Gelteq enters Product Development, Profit Share Agreement with Melbourne Health

Gelteq (GELS) announced it has entered into a Product Development and Profit Share Agreement, with Melbourne Health, operator of The Royal Melbourne Hospital and one of Australia’s top public health services with extensive research capabilities. Under the Agreement, Gelteq and Melbourne Health will develop new products incorporating high-amylose maize starch butyrylated, or HAMSB, a unique compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer. “This collaboration with Melbourne Health marks a pivotal step in translating cutting-edge clinical research into a potentially commercially viable product that could meaningfully reduce the risk of bowel cancer,” said Nathan Givoni, CEO of Gelteq. “By combining Melbourne Health’s expertise and robust research foundation with Gelteq’s innovative gel technology, we seek to deliver meaningful health benefits in a convenient, user-friendly format.”